Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01666756 · ClinicalTrials.gov registry record · Phase 1
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
A Phase 1 study of Advanced Adult Primary Liver Cancer and Adult Primary Hepatocellular Carcinoma, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01666756: Completed Phase 1 study of Advanced Adult Primary Liver Cancer and Adult Primary Hepatocellular Carcinoma, sponsored by City of Hope Medical Center.
NCT01666756 is a Phase 1 study of Advanced Adult Primary Liver Cancer and Adult Primary Hepatocellular Carcinoma that has completed, run by City of Hope Medical Center. The registered enrollment target is 18 participants, below the 28-participant average among 7 other Advanced Adult Primary Liver Cancer trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01666756, a Phase 1 study of Advanced Adult Primary Liver Cancer and Adult Primary Hepatocellular Carcinoma, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best dose of Chinese herbal formulation PHY906 when given together with sorafenib tosylate in treating patients with advanced liver cancer. Biological therapies, such as Chinese herbal formulation PHY906, may interfere with the growth of tumor cells and slow the growth of tumors. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib tosylate may also stop the growth of liver cancer by blocking blood flow to the tumor. Giving Chinese herbal formulation PHY906 together with sorafenib tosylate may work better in treating advanced liver cancer.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG sorafenib tosylate
- DIETARY_SUPPLEMENT Chinese herbal formulation PHY906
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2014-06-11 |
| Est. Completion | 2020-05-29 |
| Phase | Phase 1 |
What the finished NCT01666756 record still lists
NCT01666756 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 28-participant average among 7 other Advanced Adult Primary Liver Cancer trials with a reported enrollment target (36% lower).
The record links to 5 conditions, with Advanced Adult Primary Liver Cancer appearing as the primary indexed condition, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01666756 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01666756 about?
NCT01666756 is a clinical study titled "Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer". This phase I trial studies the side effects and best dose of Chinese herbal formulation PHY906 when given together with sorafenib tosylate in treating patients with advanced liver cancer. Biological therapies, such as Chinese herbal formulation PHY906, may interfere with the growth of tumor cells an...
What is the current status of trial NCT01666756?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2014-06-11. Estimated completion is 2020-05-29.
What conditions does trial NCT01666756 study?
This clinical trial studies the following conditions: Advanced Adult Primary Liver Cancer, Adult Primary Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage B Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma.
What interventions are being tested in trial NCT01666756?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), sorafenib tosylate (DRUG), Chinese herbal formulation PHY906 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01666756?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01666756 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Adult Primary Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
COMPLETED · Phase 1
-
Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction
COMPLETED · Phase 1
-
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
COMPLETED · Phase 1
-
TSR-022 (anti-TIM-3 Antibody) and TSR-042 (anti-PD-1 Antibody) in Patients with Liver Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI